Basel, Switzerland – This week Novartis released topline results from the Phase III APPEAR-C3G study showing that its oral factor B inhibitor iptacopan significantly reduced protein in the urine of patients with C3 glomerulopathy, an ultra-rare and progressive kidney disease. In APPEAR-C3G, twice-daily treatment with 200-mg iptacopan—when given on top...
Latest News
Basel, Switzerland – A new way to treat a painful skin condition shows promise in a phase 2 trial, according to a late-breaking presentation at the American Academy of Dermatology (AAD) Association annual meeting. Novartis’ remibrutinib was well tolerated and showed high responder rates compared with placebo in patients with...
CHICAGO – A newly developed artificial intelligence (AI) system that analyzes specialized MRIs of the brain accurately diagnosed children between the ages of 24 and 48 months with autism at a 98.5% accuracy rate, according to research being presented next week at the annual meeting of the Radiological Society of...
Sendai, Japan – Researchers at Tohoku University have discovered a new approach for treating lymph node metastasis. Anticancer drugs are administered directly into the LNs under ultrasound guidance (Lymphatic Drug Delivery System or LDDS) to target sentinel lymph nodes (LNs) and generate antitumor effects locally, preventing distant metastasis. This approach...
Leicester, UK – A novel approach to studying the progression of tuberculosis (TB) from infection to disease has identified and treated people at increased risk of developing the disease that current methods of testing would not. Researchers at the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research...
Researchers at DZNE and Charité – Universitätsmedizin Berlin have pioneered a novel treatment for Anti-NMDA Receptor Encephalitis. By reprogramming white blood cells to target and eliminate disease-causing cells, the approach offers a new level of precision and efficiency. The technique has proven successful in laboratory studies, clinical trials in humans...
CHICAGO – A newly developed artificial intelligence (AI) system that analyzes specialized MRIs of the brain accurately diagnosed children between the ages of 24 and 48 months with autism at a 98.5% accuracy rate, according to research being presented next week at the annual meeting of the Radiological Society of...
A new technical poster, available from Agilent Automation Solutions, describes how researchers at I-STEM (Evry, France) have used a BioCel 1800 platform to automate high content screening of small molecules for muscular dystrophy therapeutic research. The described research shows the utility of the BioCel platform in performing automated screens on...
SAN DIEGO, CA ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to...
Dresden, Germany – Tuberculosis (TB) is a prevalent infectious disease that affects millions of people each year. It was previously the leading cause of death from a single pathogen before the COVID-19 pandemic. Detecting TB early is challenging because the bacterium Mycobacterium tuberculosis (Mtb) can hide in human macrophages, which...